The University of Edinburgh has launched more than 500 startup and spinout companies since our first spinout, Reynolds Medical Ltd, was formed in 1967 to commercialise a portable heart monitor. In our latest full year (2018-19) Edinburgh Innovations helped launch 68 companies, including 14 founded by University staff.
Our entrepreneurs have an enviable record of success and company longevity. A recent survey of high-growth opportunities by Beauhurst, a data provider for investors, found Edinburgh to be the leading university in Scotland for spinouts – companies based on University research. Of spinouts created since 2010, 85% are still trading – a far higher survival rate than the UK average.
Our startups and spinouts regularly attract investment from leading venture funds. In the current financial year, our client companies have attracted a record £35 million to date.
Portfolio of spinout companies
Carbogenics has developed a low carbon technology to convert difficult-to-recycle and low-value waste into a range of high-value products. Its first product CreChar is an additive for anaerobic digestion capable of increasing the output of biogas plants by at least 15%.
Particle Analytics has developed technology for advanced visualisation and analysis of industrial particle simulations, particularly in identifying potential erosion failures through fine grained analysis.
Sofant is developing smart antenna™ technology which dramatically reduces the cost of producing and operating wireless network equipment while improving performance, simplifying design and reducing power consumption.
Position triangulation using a mobile device with no additional infrastructure, in areas where GPS satellite signals are weak or blocked, such as indoors or in dense urban areas. Tencet is a customer.
Personalised synthetic voices for use in communication aids by individuals who have lost or will lose the ability to speak using the individual’s own voice or blended recordings matching characteristics.
Development of new therapies for Multiple Sclerosis. Ground breaking research aims to identify remyelinating agents that enhance the repair of damaged myelin sheaths in MS patients.